Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for reduced cardiovascular risk

Philip R. Liebson, Ezra A Amsterdam

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) in patients with vascular disease or high-risk diabetes, as the largest published comparative trial of these agent classes, provides further evidence concerning the comparison between the angiotensin-receptor blockers (ARBs) and the angiotensin-converting enzyme inhibitors (ACEIs). In this trial, telmisartan (an ARB) was non-inferior to ramipril (an ACEI) in reducing fatal and nonfatal cardiovascular events. Moreover, ONTARGET is an example of a high-quality noninferiority trial. However, the combination of the 2 agents was associated with more adverse effects without an increase in benefit. The study differed from several other comparative studies in which the dose and choice of ACEI was left to individual physicians. Further, in ONTARGET, the ACEI was not titrated to the maximum dose and patients with heart failure were excluded.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalPreventive Cardiology
Volume12
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Ramipril
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists
Vascular Diseases
Heart Failure
Physicians
telmisartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Public Health, Environmental and Occupational Health

Cite this

@article{df57bb06f4a34115a9f68ec0e2df8cfa,
title = "Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for reduced cardiovascular risk",
abstract = "The recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) in patients with vascular disease or high-risk diabetes, as the largest published comparative trial of these agent classes, provides further evidence concerning the comparison between the angiotensin-receptor blockers (ARBs) and the angiotensin-converting enzyme inhibitors (ACEIs). In this trial, telmisartan (an ARB) was non-inferior to ramipril (an ACEI) in reducing fatal and nonfatal cardiovascular events. Moreover, ONTARGET is an example of a high-quality noninferiority trial. However, the combination of the 2 agents was associated with more adverse effects without an increase in benefit. The study differed from several other comparative studies in which the dose and choice of ACEI was left to individual physicians. Further, in ONTARGET, the ACEI was not titrated to the maximum dose and patients with heart failure were excluded.",
author = "Liebson, {Philip R.} and Amsterdam, {Ezra A}",
year = "2009",
doi = "10.1111/j.1751-7141.2008.00010.x",
language = "English (US)",
volume = "12",
pages = "43--50",
journal = "Preventive Cardiology",
issn = "1520-037X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)

T2 - Implications for reduced cardiovascular risk

AU - Liebson, Philip R.

AU - Amsterdam, Ezra A

PY - 2009

Y1 - 2009

N2 - The recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) in patients with vascular disease or high-risk diabetes, as the largest published comparative trial of these agent classes, provides further evidence concerning the comparison between the angiotensin-receptor blockers (ARBs) and the angiotensin-converting enzyme inhibitors (ACEIs). In this trial, telmisartan (an ARB) was non-inferior to ramipril (an ACEI) in reducing fatal and nonfatal cardiovascular events. Moreover, ONTARGET is an example of a high-quality noninferiority trial. However, the combination of the 2 agents was associated with more adverse effects without an increase in benefit. The study differed from several other comparative studies in which the dose and choice of ACEI was left to individual physicians. Further, in ONTARGET, the ACEI was not titrated to the maximum dose and patients with heart failure were excluded.

AB - The recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) in patients with vascular disease or high-risk diabetes, as the largest published comparative trial of these agent classes, provides further evidence concerning the comparison between the angiotensin-receptor blockers (ARBs) and the angiotensin-converting enzyme inhibitors (ACEIs). In this trial, telmisartan (an ARB) was non-inferior to ramipril (an ACEI) in reducing fatal and nonfatal cardiovascular events. Moreover, ONTARGET is an example of a high-quality noninferiority trial. However, the combination of the 2 agents was associated with more adverse effects without an increase in benefit. The study differed from several other comparative studies in which the dose and choice of ACEI was left to individual physicians. Further, in ONTARGET, the ACEI was not titrated to the maximum dose and patients with heart failure were excluded.

UR - http://www.scopus.com/inward/record.url?scp=63849189587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849189587&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7141.2008.00010.x

DO - 10.1111/j.1751-7141.2008.00010.x

M3 - Article

C2 - 19301691

AN - SCOPUS:63849189587

VL - 12

SP - 43

EP - 50

JO - Preventive Cardiology

JF - Preventive Cardiology

SN - 1520-037X

IS - 1

ER -